RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $18
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Conor McNamara has maintained an 'Outperform' rating on Maravai LifeSciences (NASDAQ:MRVI) but lowered the price target from $20 to $18.

August 08, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Maravai LifeSciences' price target has been lowered from $20 to $18 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100